{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:48:57Z","timestamp":1777265337795,"version":"3.51.4"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Combination therapy with the PARP inhibitor niraparib and the androgen-receptor inhibitor abiraterone acetate plus prednisone (AAP) has recently shown improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations, particularly BRCA1\/2, in the phase III MAGNITUDE trial. Evidence outside clinical trials remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the clinical courses of five consecutive patients with HRR-mutated mCRPC treated with niraparib (200 mg once daily) plus abiraterone acetate (1000 mg once daily) and prednisone (5 mg twice daily) at our institution. Baseline characteristics, PSA kinetics (including time to PSA 50% decline), radiological responses, progression-free survival (PFS; defined as a composite clinical, radiological, and biochemical endpoint), overall survival (OS), and safety outcomes were assessed. All patients underwent radiological evaluation every three months, including contrast-enhanced CT of the chest and abdomen and bone scintigraphy. Tumor response was assessed according to RECIST 1.1 criteria for measurable disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients harbored pathogenic HRR gene alterations: somatic and\/or germline BRCA1\/2 (three BRCA2, two BRCA1), and one patient with concurrent PALB2. Median age at therapy initiation was 70 years (range 60\u201380). Three patients (Patients 1, 4, 5) achieved significant and sustained PSA declines (\u226550%) and prolonged disease control, including elderly and frail individuals. Two patients (Patients 2, 3) exhibited early progression with limited clinical benefit, consistent with aggressive disease course. Median PFS varied widely across the cohort, reflecting heterogeneity of clinical phenotypes. Treatment was generally manageable; dose interruptions or reductions were required in selected cases, with no new safety signals observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Niraparib\u2013abiraterone demonstrated anti-tumor activity in a subset of HRR-mutated mCRPC patients, including elderly and frail individuals. However, the very small sample size, retrospective design, and absence of standardized rPFS assessment limit generalizability. These findings are primarily hypothesis-generating but align with prospective trial results and underscore the heterogeneity of HRR-mutated mCRPC, highlighting the need for individualized therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1799304","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:28Z","timestamp":1777264108000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Niraparib\u2013abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five cases"],"prefix":"10.3389","volume":"16","author":[{"given":"Ismaela Anna","family":"Vascotto","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Venturini","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Calandrelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mancini","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pratesi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Izzi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Francini","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence","place":["Florence, Italy"]},{"name":"Clinical Oncology, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence","place":["Florence, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01649","article-title":"Niraparib and abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: results from the MAGNITUDE trial","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"B6","volume-title":"Common terminology criteria for adverse events (CTCAE) version 5.0","year":"2017"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S411023","article-title":"Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends","volume":"16","author":"Thapa","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01141-9","article-title":"The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"20","author":"Pinterpe","year":"2025","journal-title":"Target Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000003338","article-title":"Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data","volume":"112","author":"Zhang","year":"2026","journal-title":"Int J Surg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/ph18071015","article-title":"PARP inhibitors in mCRPC: systematic review and meta-analysis","volume":"18","author":"Laurberg","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.08.011","article-title":"Variant allele frequency: a decision-making tool in precision oncology","volume":"9","author":"Boscolo Bielo","year":"2023","journal-title":"Trends Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00345","article-title":"Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with homologous recombination deficiency","volume":"4","author":"Sokol","year":"2020","journal-title":"JCO Precis Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:28:28Z","timestamp":1777264108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":13,"alternative-id":["10.3389\/fonc.2026.1799304"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1799304","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1799304"}}